Insider · CIK 0001817988
Susan ALTSCHULLER
Files at CLYM (Eliem Therapeutics, Inc.), CERE (Cerevel Therapeutics Holdings, Inc.), MURA (Mural Oncology plc). First filing Dec 21, 2023, latest Dec 21, 2023.
In brief
Susan ALTSCHULLER files SEC Form 4 as CFO and director at CERE (Cerevel Therapeutics Holdings, Inc.), and also at CLYM (Eliem Therapeutics, Inc.), MURA (Mural Oncology plc). Since Dec 21, 2023, Susan ALTSCHULLER has reported 0 open-market buys worth $0 and 1 open-market sell worth $572k, the latest filed on Dec 21, 2023.
A track record needs three past buys with six months of prices behind them; Susan ALTSCHULLER has 0, so none is measured yet.
The newest scored trade: sold $572k of CERE on Dec 20, 2023, filed Dec 21, 2023, scored 51 (moderate).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 51Moderate | Cerevel Therapeutics Holdings, Inc. | $572k 13,808 shares | -45% | - |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 6, 2026 | CLYM Eliem Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +142,500 | $0.00 | $0 | 142,500 | Jan 8, 2026 |
| Oct 1, 2025 | CLYM Eliem Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Oct 1, 2025 |
| May 30, 2024 | MURA Mural Oncology plc | AGrant or award Stock Option (right to buy)derivative | +8,462 | $0.00 | $0 | 8,462 | Jun 5, 2024 |
| May 30, 2024 | MURA Mural Oncology plc | AGrant or award Stock Option (right to buy)derivative | +8,462 | $3.35 | $28k | 8,462 | Jun 3, 2024 |
| Jan 19, 2024 | CERE Cerevel Therapeutics Holdings, Inc. | AGrant or award Restricted Stock Unitsderivative | +81,065 | $0.00 | $0 | 81,065 | Jan 23, 2024 |
| Dec 19, 2023 | CERE Cerevel Therapeutics Holdings, Inc. | MOption exercise Common Stock | +30,721 | - | - | 30,721 | Dec 21, 2023 |
| Dec 20, 2023 | CERE Cerevel Therapeutics Holdings, Inc. | SOpen-market sale Common Stock | -13,808 | $41.42 | $572k | 16,913 | Dec 21, 2023 |
| Dec 19, 2023 | CERE Cerevel Therapeutics Holdings, Inc. | MOption exercise Restricted Stock Unitsderivative | -30,721 | $0.00 | $0 | 0 | Dec 21, 2023 |
| Dec 14, 2023 | MURA Mural Oncology plc | AGrant or award Stock Option (right to buy)derivative | +15,021 | $0.00 | $0 | 15,021 | Dec 18, 2023 |
Questions about Susan ALTSCHULLER
Answered from the filings on this page, as of the latest one.
Is Susan ALTSCHULLER buying or selling?
Not in the last 12 months. Susan ALTSCHULLER's latest open-market trade on SEC Form 4 was sold $572k of CERE on Dec 20, 2023.
How did Susan ALTSCHULLER's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Susan ALTSCHULLER has 0.
Where does Susan ALTSCHULLER file Form 4?
Susan ALTSCHULLER has filed Form 4 at CERE (Cerevel Therapeutics Holdings, Inc.) as Chief Financial Officer; CLYM (Eliem Therapeutics, Inc.) as Chief Financial Officer; MURA (Mural Oncology plc). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.